Showing results (181-190 of 203) with videos related to
Sort By:
Pageof 21
Oncoimmunology|September 26, 2015
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patientsNeil L Berinstein, Mohan Karkada, Amit M Oza, et al.Plos One|August 31, 2013
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerOtto Metzger-Filho, Aurélie Catteau, Stefan Michiels, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.The Lancet. Oncology|July 3, 2021
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology researchPriya Ranganathan, Girish Chinnaswamy, Manju Sengar, et al.Molecular Cancer Therapeutics|November 5, 2016
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of LapatinibMichael F Press, Catherine E Ellis, Robert C Gagnon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III TrialJ Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.European Heart Journal|March 23, 2017
Improving public health by improving clinical trial guidelines and their applicationMartin J Landray, Jeroen J Bax, Laurence Alliot, et al.Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.Pageof 21